



Viscoelastic Testing: Role & Target

Sandro Rizoli, MD PhD FRCSC FACS

Professor Surgery & Critical Care Medicine

Medical Director Trauma & Acute Care Surgery

President Panamerican Trauma Society


St. Michael's

Inspired Care. Inspiring Science.

Disclosure

KCI Canada
CSL Behring
NovoNordisk

more ROTEM – SMH



Trauma Induced Coagulopathy (TIC)

- common = 25% patients
- intrinsic – immediate (*at the scene*)
- organ failure/dysfunction
- mortality 3 – 4x
- complex (*many different hemostatic defects*)

- NOT dilution, consumptive, DIC
- 1st cause preventable deaths



Stone Age

Most important determinants: who & time

21M, multiple chest/abd GSW, 1am Friday
few minutes to SMH

TTL Dr Andrew Petrosoniack
blood trauma bay

agonal breathing – finger thoracostomy
loose pulses = ED thoracotomy
heart pulsating + aorta clamp



Stone Age

anesthesia staff trauma bay – OR immediately

blown out common iliac vein + segment II liver
gross contamination (*gastric + bowel perforations*)

obvious coagulopathy

ligate vein + hepatectomy + pack abd/chest

TNICU = resuscitation (25U RBC) = 1pm back OR



Stone Age

2nd surgery, same day
no crystalloid + infusion TXA
anesthesia x2 + Dr Sholzberg

no mechanical source – blood = water

about 75U RBC +++++++
rFVIIa = first clots seen



ROTEM Tells Story (100u RBC)

	1am	7am	10am	next day
CT (43-82)	98	664	181	57
CFT (48-127)	171		755	148
A10 (43-65)	37	6	2	40
MCF (52-70)	49	12	25	52
ML (<15%)	1	0	0	1
FIBTEM A10 MCF (7-24)	7	6	2	15



Clinical Case II


elective surgery – small incision
? injury vena cava – hole not seen
coagulopathic – packed – MSICU

Few hours later:
ROTEM fully corrected but output >1.5L
Team reluctant return OR

Who is really important in resuscitation?
How important VET (role) and what target?




It is a Lab Test



1. not accurate (*Cochrane Review 2015 – research only*)
2. not validated (*Solomon; Scand J Clin Lab Invest 2016*)
3. unable differentiate dilution from low platelets
4. unable # capillary & large vessel (*Campbell JT 2015*)
5. INR faster, cheaper, better tx (*Goodman JT 2015*)
6. evidence observational trials (*Da Luz Crit Care 2014*)



It is a Lab Test



7. may increase use fibrinogen
8. variable agreement SCT (Holcomb; Ann Surg 2012)
9. requires local standard techniques
10. lack uniformity, high coefficient of variance
(Kitchen; Semin Thromb Hemost 2010)
11. different results, different centres
12. TEG # ROTEM *(Da Luz; Crit Care 2014)*
13. many variables interfere results *(Inaba; JT 2015)*



Why Bother?

1. making clinical decisions is not easy
2. time to decisions critical
3. do not know resuscitation




Managing Complex Problem

1. trauma coagulopathy NOT simple
surgical vs. coagulopathic
2. cannot # physiologic – pathologic
3. change over time
4. dynamic changes & imbalances
(thrombin generation – clot lysis)



Physiology – NOT Good





- XXI Century**
- Endogenous
 - Early
 - 25% patients
 - 3x mortality
 - Shock
 - NOT addressed



Clinical Judgment NOT Good

Organ failure – 25% patients – can't tell

Mechanical



Coagulopathic




Resuscitation Strategies NOT Good

Resuscitation: 1:1:1

Formula (*one size all*)

everyone is (*or will be*) coagulopathic
everyone needs plasma (*± platelet*)

- a. blood early
- b. restrict crystalloids
- c. no lab



Static Lab Tests NOT Good

PT-INR

warfarin, not designed dynamic measure

PTT

designed screen hemophilia
measure single CF <30%

Fibrinogen

Nothing Klaus method in MH

Dzik WH et al. Crit Care, 2011;15(6):242.



Are TEG & ROTEM Good?

1. growing evidence usefulness
2. growing clinical use
cardiac surgery, liver transplant, OB, TRAUMA

Reasons:

- *diagnose multiple defects*
- *point-of-care = time*
- *clinical useful = guide tx.*



Cost-Effective

National Institute Health Care Excellence
Commissioned systematic review (NICE)

1. add or replace conventional tests??
2. any abnormal parameter = risk transfusion
3. more effective + cheaper than SCT

*cost-effective if >80 tests/year
worth (training & implementation)*



Predict Transfusion & Mortality

Predict = maybe reduce transfusion & mortality

da Luz; Rizoli; Nascimento; Callum; Adhikari
*TEG & ROTEM diagnosis coagulopathy, transfusion
& mortality trauma. Critical Care 2014 Sep 18:518*

Veigas; Rizoli; Nascimento; da Luz
*Thresholds ROTEM diagnosis & management bleeding
trauma patients. Scand J Trauma Resusc Emerg Med 2016*



Targets

Consensus Conference on TEM-based Transfusion Guidelines for Early Trauma Resuscitation

SHERATON PHILADELPHIA UNIVERSITY CITY HOTEL
3549 Chestnut Street, Philadelphia, PA 19104

Start: Tuesday, Sept 9 2014 8:00 AM – 5:00 PM
End: Wednesday, Sept 10 2014 8:00 AM to 12:00 Noon

JTACS 2015, 78:1220



Targets

Consensus Conference – Philadelphia
Guidelines early resuscitation

Massive transfusion

EXTEM A5 ≤ 35 mm (*clot strength*)

Davenport Crit Care Med 2011, 39:1

FIBTEM A10 ≤ 7 (*lysis*) = best predictor MT

Schochl Crit Care 2011, 15:265



Targets

Any transfusion

clot strength and fibrinolysis

EXTEM/FIBTEM A5/MCF ≤ 35 mm

RBC = 35%, 88% (INR 17%;96%); FFP = 36%, 87% (INR 20%; 96%)

Davenport Crit Care Med 2011, 39:1

monitor response FC/cryo correct EXTEM/FIBTEM

stop or do not initiate transfusion (+ clinical)

Rourke J Thromb Haemost 2012, 10:1342



Targets

Mortality

low clot strength & fibrinolysis

FIBTEM MCF ≤ 7 (21% vs. 9%); EXTEM CT ≥ 100 ;

EXTEM MCF ≤ 45 (27% vs. 9%)

Fibrinolysis

FIBTEM MCF = good discriminator

Schochl J Neurotrauma 2011, 28:2033



Targets

Anti-fibrinolytics

Don't wait for abnormal test
Any lysis = give more

Platelets

Not good discriminator
Consider other tests



Gonzalez & Moore RCT

MTP directed TEG or SCT; 111 patients

Hg ≤ 10 = RBC; *INR* ≥ 1.5 = FFP;

fibrinogen < 150 = cryo; < 100,000 = plat


ACT > 140 = 2U FFP + 10U cryo + 1 plat


ACT 111-139 = 2U FFP

Angle < 63 = 10U cryo; *LY30* > 3% = TXA


TEG = > survival, more FFP/plat








Activation coagulation CT $\geq 80s$ (+ N MCF) consider **FFP**



Clot formation MCF/A10 ≤ 35 **cryo/plat**



Fibrinolysis ML=100% consider **TXA**





Derivate Parameters

Thrombin = calibrated automated thrombogram

SMH = TG associated MT & mortality

ROTEM V-curve, 550 severe

drop MaxV = increase 0.7U transfusion, mortality




TEM V-curve

Time to MaxV → MaxV-t



Clot Structure = Stability

Thrombin & fibrinogen



Fibrinogen \rightarrow fibrin monomers \rightarrow fibers/meshwork

THROMBIN

High

thinner – dense
highly branched fibers
resistant fibrinolysis


LOW

thicker fibers – network
unbranched fibers
susceptible lysis



Clot Structure = Stability

Fibrin structure (size/how compact) = stability
also clot contraction – RBC



Wolberg, Campbell *Transf Apher Sci.* 38,15 2008



St. Michael's


Inspired Care. Inspiring Science.

Clot Formation Time


CFT corresponds TEG k

Depends:

- thrombin generation
- platelet count & function
- fibrinogen concentration
- fibrin polymerization



Generate a Graph



**thrombin + platelets + fibrinogen
2 minutes**



Conclusions

Role:

lab tests – many limitations

advantages: time + guide clinical decision
part of MTP

Target:

Canadian consensus JTACS 2015

any abnormal result = concerning

CT (clotting factors); clot strength; lysis

CFT = 2 min. thrombin + plat. + fibrinogen



Thank you

